James Hambro & Partners LLP Lowers Stock Holdings in Danaher Corporation $DHR

James Hambro & Partners LLP trimmed its holdings in shares of Danaher Corporation (NYSE:DHR) by 0.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 292,961 shares of the conglomerate’s stock after selling 2,751 shares during the period. Danaher makes up approximately 2.3% of James Hambro & Partners LLP’s holdings, making the stock its 19th largest position. James Hambro & Partners LLP’s holdings in Danaher were worth $57,850,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Danaher by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock worth $12,296,123,000 after purchasing an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Danaher by 3.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after buying an additional 612,154 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Danaher by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock valued at $1,800,614,000 after buying an additional 194,466 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after buying an additional 1,450,703 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Danaher by 4.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock worth $867,168,000 after purchasing an additional 163,332 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR stock opened at $184.97 on Friday. The firm’s 50-day moving average is $199.44 and its two-hundred day moving average is $197.53. The company has a market capitalization of $132.45 billion, a PE ratio of 39.36, a price-to-earnings-growth ratio of 2.63 and a beta of 0.75. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.59. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion during the quarter, compared to analysts’ expectations of $5.83 billion. During the same quarter in the previous year, the business posted $1.72 earnings per share. The business’s quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is currently 27.23%.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of research reports. Bank of America reduced their target price on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Barclays reaffirmed an “overweight” rating and set a $225.00 target price (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Guggenheim reissued a “buy” rating and set a $250.00 target price on shares of Danaher in a research report on Wednesday, July 23rd. Evercore ISI decreased their price target on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating for the company in a report on Tuesday, July 8th. Finally, Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research note on Tuesday, September 2nd. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average target price of $245.91.

Insider Activity

In other Danaher news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 11.10% of the stock is owned by corporate insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.